Gene Variations Appear Linked to Prostate Cancer, Study
THURSDAY, Oct. 7 (HealthDay News) -- Variations in a gene for an
enzyme involved in cell energy metabolism may increase the risk of
prostate cancer, say scientists.
These genetic variations impair the enzyme phosphodiesterase 11A
(PDE11A), which helps regulate cells' responses to hormones and
other signals, according to the U.S. National Institute of Child
Health and Human Development researchers and colleagues.
They compared tissue from 50 prostate cancer patients and 287
men without the disease and identified eight variations in the
PDE11A gene that decreased the production or activity of PDE11A.
Thirty percent of prostate cancer patients had one or more of these
gene variations, compared with 10 percent of men without prostate
The study appears online in the journal
Clinical Endocrinology and Metabolism.
"Our study indicates that PDE11A one day may have a place in genetic screening for predisposition to prostate cancer," senior author Dr. Constantine Stratakis, acting director of the Intramural Research Program at the NICHD, said in an agency news release.
Previous research has linked genetic variations that inactivate
PDE11A with increased risk for testicular cancer and adrenal
It's known that the erectile dysfunction drug tadalafil (Cialis)
inhibits PDE11A, but there is no current clinical evidence linking
the drug to prostate cancer or other cancers, said the researchers.
They called for studies to examine whether tadalafil or any other
drugs might affect the prostate in men with variations in the
PDE11A gene, but noted that no clinical data has linked tadalafil
The American Cancer Society has more about
Copyright © 2010
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.